Sylvia Dobo

738 total citations
15 papers, 230 citations indexed

About

Sylvia Dobo is a scholar working on Genetics, Infectious Diseases and Epidemiology. According to data from OpenAlex, Sylvia Dobo has authored 15 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 3 papers in Infectious Diseases and 3 papers in Epidemiology. Recurrent topics in Sylvia Dobo's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), Influenza Virus Research Studies (2 papers) and Viral Infections and Outbreaks Research (2 papers). Sylvia Dobo is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), Influenza Virus Research Studies (2 papers) and Viral Infections and Outbreaks Research (2 papers). Sylvia Dobo collaborates with scholars based in United States, Italy and United Kingdom. Sylvia Dobo's co-authors include William Sheridan, Angela M. Rose, Y.S. Babu, Justin G. Julander, Travis K. Warren, Rekha G. Panchal, Sina Bavari, Pravin L. Kotian, Yahya El-Kattan and Ernest F. J. Block and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Annals of the Rheumatic Diseases and Annals of Allergy Asthma & Immunology.

In The Last Decade

Sylvia Dobo

13 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sylvia Dobo United States 6 118 68 39 36 24 15 230
Ashok Kumar Sharma India 11 71 0.6× 102 1.5× 29 0.7× 40 1.1× 68 2.8× 32 276
Maria Lúcia Alves Pedroso Brazil 11 37 0.3× 175 2.6× 26 0.7× 17 0.5× 16 0.7× 22 296
Chiara Nardi Italy 10 78 0.7× 141 2.1× 83 2.1× 22 0.6× 16 0.7× 20 365
Romualdo Mazzi Italy 8 142 1.2× 128 1.9× 20 0.5× 12 0.3× 22 0.9× 16 316
Paulo S. Silveira-Mattos Brazil 11 178 1.5× 139 2.0× 38 1.0× 48 1.3× 94 3.9× 15 330
Emma Paige Australia 8 109 0.9× 151 2.2× 23 0.6× 13 0.4× 19 0.8× 11 278
Davide Lazzarotto Italy 10 73 0.6× 74 1.1× 60 1.5× 45 1.3× 8 0.3× 21 278
Maria Elena Zannier Italy 8 63 0.5× 53 0.8× 47 1.2× 40 1.1× 8 0.3× 18 227
Hanafy Hafez Egypt 9 36 0.3× 90 1.3× 41 1.1× 31 0.9× 13 0.5× 32 262
Severien Meyers Belgium 7 105 0.9× 128 1.9× 62 1.6× 67 1.9× 25 1.0× 8 253

Countries citing papers authored by Sylvia Dobo

Since Specialization
Citations

This map shows the geographic impact of Sylvia Dobo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia Dobo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia Dobo more than expected).

Fields of papers citing papers by Sylvia Dobo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvia Dobo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia Dobo. The network helps show where Sylvia Dobo may publish in the future.

Co-authorship network of co-authors of Sylvia Dobo

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvia Dobo. A scholar is included among the top collaborators of Sylvia Dobo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvia Dobo. Sylvia Dobo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Mathis, Amanda, David Collins, Sylvia Dobo, et al.. (2022). Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects. Clinical Pharmacology in Drug Development. 11(4). 467–474. 10 indexed citations
3.
Johnston, Douglas, William R. Lumry, Aleena Banerji, et al.. (2020). Gastrointestinal (GI) Adverse Events (AEs) Observed With Berotralstat (BCX7353) Treatment for Hereditary Angioedema (HAE) are Primarily Mild, Self-limited, and Diminish with Time on Treatment. Journal of Allergy and Clinical Immunology. 145(2). AB102–AB102. 3 indexed citations
4.
Riedl, Marc A., William R. Lumry, Aleena Banerji, et al.. (2019). P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY. Annals of Allergy Asthma & Immunology. 123(5). S28–S29. 3 indexed citations
5.
Zuraw, Bruce L., William R. Lumry, A. K. Banerji, et al.. (2019). P150 ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS. Annals of Allergy Asthma & Immunology. 123(5). S27–S27. 1 indexed citations
6.
Vanchiere, John A., James T. Peterson, Priyesh Mehta, et al.. (2017). Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza. Open Forum Infectious Diseases. 4(suppl_1). S694–S694. 2 indexed citations
7.
Kotian, Pravin L., Travis K. Warren, Rekha G. Panchal, et al.. (2016). BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. Journal of Infection and Public Health. 9(3). 220–226. 137 indexed citations
8.
Cornpropst, Melanie, Sylvia Dobo, Angela M. Rose, et al.. (2016). BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects. Journal of Allergy and Clinical Immunology. 137(2). AB401–AB401. 5 indexed citations
9.
Aygören‐Pürsün, Emel, Markus Magerl, Jochen Graff, et al.. (2015). Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology. 135(2). AB192–AB192. 4 indexed citations
10.
Magerl, Markus, Emel Aygören‐Pürsün, Jochen Graff, et al.. (2015). BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study. Journal of Allergy and Clinical Immunology. 135(2). AB278–AB278. 4 indexed citations
11.
Whitley, Richard J., Simon Carson, Essack Mitha, et al.. (2014). Single dose Peramivir for the Treatment of Acute Seasonal Influenza: Integrated Analysis of Efficacy and Safety from Two Placebo-Controlled Trials. Antiviral Therapy. 20(7). 709–719. 22 indexed citations
12.
Hollister, Alan S., Sylvia Dobo, Andreas Maetzel, et al.. (2012). FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study. Annals of the Rheumatic Diseases. 71. 442–443. 12 indexed citations
13.
Dobo, Sylvia & Veda Johnson. (2000). EVALUATION AND CARE OF THE PREGNANT PATIENT WITH MINOR TRAUMA. 2(3). 707–722. 4 indexed citations
14.
Mendlowitz, Milton, et al.. (1998). The drug treatment of hypertension.. PubMed. 28. 191–5.
15.
Block, Ernest F. J., Sylvia Dobo, & Orlando C. Kirton. (1995). Compartment Syndrome in the Critically Injured following Massive Resuscitation. PubMed. 39(4). 787–791. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ashok Kumar Sharma Breakdown of academic impact, for papers by Maria Lúcia Alves Pedroso Breakdown of academic impact, for papers by Chiara Nardi Breakdown of academic impact, for papers by Romualdo Mazzi Breakdown of academic impact, for papers by Paulo S. Silveira-Mattos Breakdown of academic impact, for papers by Emma Paige Breakdown of academic impact, for papers by Davide Lazzarotto Breakdown of academic impact, for papers by Maria Elena Zannier Breakdown of academic impact, for papers by Hanafy Hafez Breakdown of academic impact, for papers by Severien Meyers
Rankless by CCL
2026